Skip to main content
SpringerLink
Log in

Development of Opioid Transdermal Delivery Systems

  • Chapter
Opiate Receptors and Antagonists

Part of the book series: Contemporary Neuroscience ((CNEURO))

  • 1018 Accesses

Abstract

Opioid therapies have been and will continue to be a vital part of opioid addiction and alcoholism treatments, as well as a vital part of chronic and acute pain management regimens. Transdermal delivery of opioid antagonists and ago nists can be advantageous in order to help improve the quality of life of many patients. This mode of drug administration offers many advantages when compared to the traditional oral route of drug delivery, including avoidance of hepatic first-pass metabolism, the potential for long-term controlled release with smoothing of the typical peak-trough plasma drug concentration profiles associated with multi ple dosing regimens, the ease of administration, and the possibility of immediate withdrawal of the treatment. Although the majority of the opioids used in clinical practice do not have ideal physicochemical properties that would allow them to reach therapeutic plasma levels by passive skin permeation, many advances have been made in the transdermal delivery of these agents with the advent of novel approaches including prodrugs, codrugs, microneedle (MN)-enhanced delivery, and other new formulation technologies. Many research and development avenues exist for the growth potential of the opioid transdermal drug delivery market in the next decade.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Friedman JD, Dello Buono FA. Opioid antagonists in the treatment of opioid-induced consti pation and pruritus. Ann Pharmacother 2001;35:85–91.

    Article  CAS  PubMed  Google Scholar 

  2. David S, Lancaster T, Stead LF. Opioid antagonists for smoking cessation. The Cochrane Database of Systematic Reviews 2001, Issue 3. Art. No.: CD003086. DOI: 10.1002/14651858. CD003086.

    Google Scholar 

  3. Ngai H, Berkowitz BA, Yang JC, Hempstead J, Spector S. Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. Anesthesiology 1976;44:398–401.

    Article  CAS  PubMed  Google Scholar 

  4. Bradberryand JC, Raebel MA. Continuous infusion of naloxone in the treatment of narcotic overdose. Drug Intell Clin Pharm 1981;15:945–950.

    Google Scholar 

  5. Gourlayand K, Coulthard K. The role of naloxone infusions in the treatment of overdoses of long half-life narcotic agonists: application to nor-methadone. Br J Clin Pharmacol 1983; 15:269–271.

    Google Scholar 

  6. Aungst J, Rogers NJ, Shefter E. Enhancement of naloxone penetration through human skin in vitro using fatty acids, fatty alcohols, surfactants, sulfoxides and amides. Int J Pharm 1986; 33:225–234.

    Article  CAS  Google Scholar 

  7. Aungst J, Blake JA, and Hussain MA. Contributions of drug solubilization, partitioning, barrier disruption, and solvent permeation to the enhancement of skin permeation of various compounds with fatty acids and amines. Pharm Res 1990;7:712–718.

    Article  CAS  PubMed  Google Scholar 

  8. Panchagnula R, Salve PS, Thomas NS, Jain AK, Ramarao P. Transdermal delivery of naloxone: effect of water, propylene glycol, ethanol and their binary combinations on permea tion through rat skin. Int J Pharm 2001;219:95–105.

    Article  CAS  PubMed  Google Scholar 

  9. Mason J, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 1994;18:1162–1167.

    Article  CAS  PubMed  Google Scholar 

  10. Mason J, Salvato FR, Williams LD, Ritvo EC, Cutler RB. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 1999;56:719–724.

    Article  CAS  PubMed  Google Scholar 

  11. Michel ME, Bolger G, Weissman BA. Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find Exp Clin Pharmacol 1985;7:175–177.

    CAS  PubMed  Google Scholar 

  12. Hamilton RJ, Olmedo RE, Shah S, Hung OL, Howland MA, Perrone J, Nelson LS, Lewin NL, Hoffman RS. Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets. Acad Emerg Med 2002;9:63–68.

    Article  PubMed  Google Scholar 

  13. Drobes DJ, Anton RF, Thomas SE, Voronin K. A clinical laboratory paradigm for evaluating med ication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology 2003;28:755–764.

    Article  CAS  PubMed  Google Scholar 

  14. Costantini LC, Kleppner SR, McDonough J, Azar MR, Patel R. Implantable technology for long-term delivery of nalmefene for treatment of alcoholism. Int J Pharm 2004;283:35–44.

    Article  CAS  PubMed  Google Scholar 

  15. Aungst B, Di Luccio, RC. Transdermal delivery of opioids. Eur Pat Appl. (1986), 25 pp.

    Google Scholar 

  16. Shevchuk I, Reidenberg, B. Transdermal dosage forms comprising a drug and a salt and free-base form of an adverse agent. PCT Int Appl 2004; 51.

    Google Scholar 

  17. Crabtree BL. Review of naltrexone, a long acting opiate antagonist. Clin Pharm 1984;3: 273–280.

    CAS  PubMed  Google Scholar 

  18. Gonzalez JP, Brogden RN. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988;35: 192–213.

    Article  CAS  PubMed  Google Scholar 

  19. Volpicelli JR, Alterman AI, Hayashida M. NTX in the treatment of alcohol dependence. Arch Gen Psychiatry 1992;49:876–880.

    CAS  PubMed  Google Scholar 

  20. Terenius L. Rational treatment of addiction. Curr Opin Chem Biol 1998;2:541–547.

    Article  CAS  PubMed  Google Scholar 

  21. Meyer MC, Straughn AB, Lo MW, Schary WL, Whitney CC. Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry 1984;45:15–19.

    CAS  PubMed  Google Scholar 

  22. Wall M, Brine DR, Perez RM. Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metab Dispos 1981;9:369–375.

    CAS  PubMed  Google Scholar 

  23. Kranzler HR, Lowe VM, Kirk J V. Naltrexone vs nefazodone for treatment of alcohol depend ence. A placebo controlled trial. Neuropsychopharmacology 2000;22:493–503.

    Article  CAS  PubMed  Google Scholar 

  24. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AL, O'Brien CP. Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 1997;54:737–742.

    CAS  PubMed  Google Scholar 

  25. Verebey K. The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics. NIDA Res Monogr 1980;28:147–158.

    Google Scholar 

  26. Croop RS, Faukner EB, and Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Results from the multicentre usage study. The naltrexone usage group study. Arch Gen Psychiatry 1997;54:1130–1135.

    CAS  PubMed  Google Scholar 

  27. King AC, Volpicelli JR, Gunduz M, O'Brien CP, Kreek MJ. Naltrexone biotransforma-tion and incidence of subjective side effects: a preliminary study. Alcohol Clin Exp Res 1997;21:906–909.

    CAS  PubMed  Google Scholar 

  28. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006;63:210–218.

    Article  CAS  PubMed  Google Scholar 

  29. Liu Y, Sunderland VB, O'Neil AG. In vitro and in vivo release of naltrexone from biodegradable depot systems. Drug Dev Ind Pharm 2006;32:85–94.

    Article  CAS  PubMed  Google Scholar 

  30. Galloway GP, Koch M, Cello R, Smith DE. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial. BMC Psychiatry 2005;5:18.

    Article  PubMed  Google Scholar 

  31. Chen YL, Chun LL, Enscore DJ. Transdermal therapeutic systems for the administration of naloxone, naltrexone, and nalbuphine. U.S. Patent No. 4,573,995 (March 4, 1986).

    Google Scholar 

  32. Vereby K, Volavka J, Mule SJ, Resnick RB. Naltrexone: disposition, metabolism and effects after acute and chronic dosing. Clin Pharmacol Ther 1976;20:315–328.

    Google Scholar 

  33. Hussain MA, Koval CA, Myers MJ, Shami EG, Shefter E. Improvement of the oral bioavail-ability of naltrexone in dogs. J Pharm Sci 1987;76:356–358.

    Article  CAS  PubMed  Google Scholar 

  34. Hussain MA, Aungst BJ, Koval CA, Shefter E. Improved buccal delivery of opioid analgesics and antagonists with bitterless prodrugs. Pharm Res 1988;5:615–618.

    Article  CAS  PubMed  Google Scholar 

  35. Stinchcomb AL, Swaan PW, Ekabo O, Harris KK, Browe J, Hammell DC, Cooperman TA, Pearsall M. Straight-chain naltrexone ester prodrugs: diffusion and concurrent esterase bio-transformation in human skin. J Pharm Sci 2002;91:2571–2578.

    Article  CAS  PubMed  Google Scholar 

  36. Hammell DC, Hamad M, Vaddi HK, Crooks PA, Stinchcomb AL. A duplex “Gemini” prodrug of naltrexone for transdermal delivery. J Control Release 2004;97:283–290.

    Article  CAS  PubMed  Google Scholar 

  37. Rautio J, Nevalainen T, Taipale H, Vepsäläinen J, Gynther J, Pedersen T, Järvinen T, Synthesis and in vitro evaluation of aminoacyloxyalkyl esters of 2-(6-methoxy-2-naphthyl) propionic acid as novel naproxen prodrugs for dermal delivery. Pharm Res 1999;16:1172–1178.

    Article  CAS  PubMed  Google Scholar 

  38. Rossi L, Dominici S, Serafini S, Casabianca A, Cerasi A, Chiarantini L, Celeste AG, Cappellacci L, Franchetti P, Grifantini M, Magnani M. Pharmacokinetic and antiretroviral activity in mice of oral [P1,P2-bis[2-(adenin-9-yl)ethoxymethyl] phosphonate], a prodrug of 9-(2-phosphonylmethoxyethyl) adenine. J Antimicrob Chemother 2002;50:365–374.

    Article  CAS  PubMed  Google Scholar 

  39. Pillai O, Hamad MO, Crooks PA, Stinchcomb AL. Physicochemical evaluation, in vitro human skin diffusion, and concurrent biotransformation of 3-O-alkyl carbonate prodrugs of naltrexone. Pharm Res 2004;21:1146–1152.

    Article  CAS  PubMed  Google Scholar 

  40. Vaddi HK, Hamad MO, Chen J, Banks SL, Crooks PA, Stinchcomb AL. Human skin permeation of branched-chain 3-0-alkyl ester and carbonate prodrugs of naltrexone. Pharm Res 2005;22:758–765.

    Article  CAS  PubMed  Google Scholar 

  41. Hammell DC, Stolarczyk EI, Klausner M, Hamad MO, Crooks PA, Stinchcomb AL. Bioconversion of naltrexone and its 3-O-alkyl-ester prodrugs in a human skin equivalent. J Pharm Sci 2005;94:828–836.

    Article  CAS  PubMed  Google Scholar 

  42. Valiveti S, Hammell DC, Paudel KS, Hamad MO, Crooks PA, Stinchcomb AL. In vivo evalu ation of 3-O-alkyl ester transdermal prodrugs of naltrexone in hairless guinea pigs. J Control Release 2005;102:509–520.

    Article  CAS  PubMed  Google Scholar 

  43. Valiveti S, Paudel KS, Hammell DC, Hamad MO, Chen J, Crooks PA, Stinchcomb AL. In vitro/in vivo correlation of transdermal naltrexone prodrugs in hairless guinea pigs. Pharm Res 2005;22:981–989.

    Article  CAS  PubMed  Google Scholar 

  44. Nalluri BN, Milligan C, Chen J, Crooks PA, Stinchcomb AL. In vitro release studies on matrix type transdermal drug delivery systems of naltrexone and its acetyl prodrug. Drug Dev Ind Pharm 2005;31:871–877.

    Article  CAS  PubMed  Google Scholar 

  45. Banks S, Pinninti RR, Gill HS, Prausnitz MR, Stinchcomb AL. In Vitro Permeation Studies of Naltrexone Base and Hydrochloride with Microneedle-Treated Hairless Guinea Pig Skin. Controlled Release Society. 2005: Miami, FL. USA.

    Google Scholar 

  46. Kaushik S, Hord AH, Denson DD, McAllister DV, Smitrs S, Allen MG, Prausnitz MR. Lack of pain associated with microfabricated microneedles. Anesth Analg 2001;92:502–504.

    Article  CAS  PubMed  Google Scholar 

  47. Cone EJ, Gorodetzky CW, Yeh SY. The urinary excretion profile of naltrexone and metabo lites in man. Drug Metab Dispos 1974;2:506–512.

    CAS  PubMed  Google Scholar 

  48. Reuning RH, Malspeis L, Frank S, Notari RE. Testing of drug delivery system for use in the treatment of narcotic addiction. Natl Inst Drug Abuse Res Monogr Ser 1975;4:43–45.

    PubMed  Google Scholar 

  49. Ferrari A, Bertolotti M, Dell'Utri A, Avico U, Sternieri E. Serum time course of naltrexone and 6 beta-naltrexol levels during long-term treatment in drug addicts. Drug Alcohol Depend 1998;52:211–220.

    Article  CAS  PubMed  Google Scholar 

  50. Rukstalis M, Stromberg MF, O'Brien CP, Volpicelli JR. 6-b-Naltrexol reduces alcohol con sumption in rats. Alcohol Clin Exp Res 2000;24:1593–1596.

    CAS  PubMed  Google Scholar 

  51. McCaul ME, Wand GS, Rohde C, Lee SM. Serum 6-beta-naltrexol levels are related to alco hol responses in heavy drinkers. Alcohol Clin Exp Res 2000;24:1385–1391.

    Article  CAS  PubMed  Google Scholar 

  52. Davis RD, Nelson WL. Isothiocyanate-substituted benzyl ether opioid receptor ligands derived from 6-Beta-Naltrexol. J Med Chem 1995;38:570–579.

    Article  CAS  PubMed  Google Scholar 

  53. Fujimoto JM, Roerig S, Wang RI, Chatterjie N, Inturrisi CE. Narcotic antagonist activity of several metabolites of naloxone and naltrexone tested in morphine dependent mice (38558). Proc Soc Exp Biol Med 1975;148:443–448.

    CAS  PubMed  Google Scholar 

  54. Blumberg H, Ikeda C. Comparison of naltrexone and 6-b-naltrexol for narcotic antagonist action in rats and mice. Fed Proc 1976;35:469.

    Google Scholar 

  55. Porter SJ, Somogyi AA, White JM. In vivo and in vitro potency studies of 6-b-naltrexol, the major human metabolite of naltrexone. Addict Biol 2002;7:219–225.

    Article  CAS  PubMed  Google Scholar 

  56. Brewer C. Serum naltrexone and 6-beta-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases. Addict Biol 2002;7:321–323.

    Article  PubMed  Google Scholar 

  57. Stromberg MF, Rukstalis MR, Scott AM, Volpicelli JR, O'Brien CP. A comparison of the effects of 6-b-naltrexol and naltrexone on the consumption of ethanol or sucrose using a limited-access procedure in rats. Pharmacol Biochem Behav 2002;72:483–490.

    Article  CAS  PubMed  Google Scholar 

  58. McCaul M, Sullivan J, Mumford G, Quigley J. 6-beta-naltrexol level predicts alcohol relapse (abstract). Alcohol Clin Exp Res 1997;21:32A.

    Google Scholar 

  59. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and copying skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 1992;49:881–887.

    PubMed  Google Scholar 

  60. Paudel KS, Nalluri BN, Hammell DC, Valiveti S, Kiptoo P, Hamad MO, Crooks PA, Stinchcomb AL. Transdermal delivery of naltrexone and its active metabolite 6-beta-naltrexol in human skin in vitro and guinea pigs in vivo. J Pharm Sci 2005;94:1965–75.

    Article  CAS  PubMed  Google Scholar 

  61. Johnston JA, Fiedler-Kelly J, Glover ED, Sachs DP, Grasela TH, DeVeaugh-Geiss J. Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob Res 2001;3:131–140.

    Article  CAS  PubMed  Google Scholar 

  62. Schroeder DH. Metabolism and kinetics of bupropion. J Clin Psychiatry 1983;44:79–81.

    CAS  PubMed  Google Scholar 

  63. Belson MG, Kelley TR. Bupropion exposures: clinical manifestations and medical outcome. J Emerg Med 2002;23:223–230.

    Article  PubMed  Google Scholar 

  64. Kiptoo PK, Hamad MO, Crooks PA, Stinchcomb AL. Enhancement of transdermal delivery of 6-β-naltrexol via a codrug linked to hydroxybupropion. J Control Release 2006;113:137–145.

    Article  CAS  PubMed  Google Scholar 

  65. Barber D. The physiology and pharmacology of pain: a review of opioids. J Perianesth Nurs 1997;12:95–99.

    Article  CAS  PubMed  Google Scholar 

  66. Sittl R, Nuijten M, Nautrup BP. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Clin Ther 2005;27:1022–1031.

    Article  CAS  PubMed  Google Scholar 

  67. Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain and Symptom Management 2005;29:297–326.

    Article  CAS  Google Scholar 

  68. Rieg-Falson F, Huertas L, Blouquin P, Conrath G, Couarraze G. Characterization of the enhanc ing effect of a vehicle in a transdermal system. Drug Dev Ind Pharm 1989;15:2393–2406.

    Article  CAS  Google Scholar 

  69. Monti D, Giannelli R, Chetoni P, Burgalassi S. Comparison of the effect of ultrasound and of chemical enhancers on transdermal permeation of caffeine and morphine through hairless mouse skin in vitro. Int J Pharm 2001;229:131–137.

    Article  CAS  PubMed  Google Scholar 

  70. Morimoto Y, Wada Y, Seki T, Sugibayashi K. In-vitro skin permeation of morphine hydrochlo-ride during the finite application of penetration-enhancing system containing water, ethanol and l-menthol. Biol Pharm Bull 2002;25:134–136.

    Article  CAS  PubMed  Google Scholar 

  71. Bundgaard H, Christrup L, Drustrup J, Fullerton A, Nicklasson M. Transdermal delivery of prodrug derivatives of morphine. PCT Int Appl 1992;18 pp.

    Google Scholar 

  72. Maury P, Bevan B, Teillaud E, Herrenknecht C, Falson-Rieg F, Couarraze G. In-vitro model of the transdermal transport of morphine hydrochloride by iontophoresis. Congr Int Technol Pharm 1989;3:304–313.

    CAS  Google Scholar 

  73. Gentil C, Mikler C, Teillaud E. In-vitro evaluation of transdermal iontophoretic delivery of morphine hydrochloride across animal and human skin. Proceedings of the International Symposium on Controlled Release of Bioactive Materials 1994.

    Google Scholar 

  74. Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharm 2000;38:59–89.

    Article  CAS  Google Scholar 

  75. Ashburn MA, Stephen RL, Ackerman E, Petelenz TJ, Hare B, Pace NL, Hofman AA. Iontophoteric delivery of morphine for postoperative analgesia. J Pain Symptom Manage 1992; 7:27–33.

    Article  CAS  PubMed  Google Scholar 

  76. Westerling D, Hoglund P, Lundin S, Svedman P. Transdermal administration of morphine to healthy subjects. Br J Clin Pharmacol 1994;37:571–576.

    CAS  PubMed  Google Scholar 

  77. Nishihara Y, Hirano K, Yamada H, Takehara M. Transdermal preparations containing mor phines and monoglycerides. Jpn Kokai Tokkyo Koho 1990.

    Google Scholar 

  78. Shevchuk I, Reidenberg B. Transdermal dosage forms comprising a drug and a salt and free-base form of an adverse agent. PCT Int Appl 2004;51 pp.

    Google Scholar 

  79. Hashimoto M, Fukuda M, Azuma M. Transdermal preparations of morphine hydrochloride or sulfate. Jpn Kokai Tokkyo Koho 1994.

    Google Scholar 

  80. Nishimuro S, Hanyu H, Okada Y, Shindo C. Transdermal preparations containing basic drugs in microemulsions. Jpn Kokai Tokkyo Koho 2001.

    Google Scholar 

  81. Duragesic® (fentanyl transdermal system). ALZA Corp. Feb. (2005) <http://www.duragesic.com/active/janus/en_US/assets/common/company/pi/duragesic.pdf>.

  82. Ross JR, Quigley C. Trasdermal fentanyl: informed prescribing is essential. Eur J Pain 2003; 7:481–483.

    Article  CAS  PubMed  Google Scholar 

  83. Reynolds L, Rauck R, Webster L, DuPen S, Heinze E, Portenoy R, Katz N, Charapata S, Wallace M, Fisher DM. Relative analgesic potency of fentanyl and sufentanil during intermediate-term infusions in patients after long-term opioid treatment for chronic pain. Pain 2004;110:182–188.

    Article  CAS  PubMed  Google Scholar 

  84. Transdermal sufentanil patch. Durtec. May. (2006) <http://www.durect.com/wt/durect/page_name/trans_sufentanil>.

  85. Downing JW, Leary WP, White ES. Buprenorphine: a new potent long-acting synthetic anal gesic. Comparison with morphine. Br J Anaesth 1977;49:251–255.

    Article  CAS  Google Scholar 

  86. Gilman AG, Goodman LS, Rall TW, Murad F. In Goodman and Gilman's The pharmaco logical basis of Therapeutics, Gilman AG, Goodman LS (eds.), 1985, Macmillan Publishing Company, New York, pp. 523–524.

    Google Scholar 

  87. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992;267:2750–2755.

    Article  CAS  PubMed  Google Scholar 

  88. Stinchcomb AL, Dua R, Paliwal A, Woodard RW, Flynn GL. A solubility and related physicochemical property comparison of buprenorphine and its 3-alkyl esters. Pharm Res 1995;12:1526–1529.

    Article  CAS  PubMed  Google Scholar 

  89. Imoto H, Zhou Z, Stinchcomb AL, Flynn GL. Transdermal prodrug concepts: permeation of buprenorphine and its alkyl esters through hairless mouse skin and influence of vehicles. Biol Pharm Bull 1996;19:263–267.

    CAS  PubMed  Google Scholar 

  90. Stinchcomb AL, Paliwal A, Dua R, Imoto H, Woodard RW, Flynn GL. Permeation of buprenor-phine and its 3-alkyl-ester prodrugs through human skin. Pharm Res 1996;13:1519–1523.

    Article  CAS  PubMed  Google Scholar 

  91. Evans HC and Easthope SE. Transdermal Buprenorphine. Drugs 2003;63:1999–2010.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, University of Kentucky College of Pharmacy, Lexington, Kentucky, 40536-0082

    Kalpana S. Paudel, Stan L. Banks, Paul K. Kiptoo, Dana C. Hammell, R. Reddy Pinninti, Caroline Strasinger & Audra L. Stinchcomb

Authors
  1. Kalpana S. Paudel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stan L. Banks
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul K. Kiptoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dana C. Hammell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Reddy Pinninti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Caroline Strasinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Audra L. Stinchcomb
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Life Sciences/Toxicology, Alkermes, Inc., Cambridge, MA, 02139, USA

    Reginald L. Dean III

  2. Department of Pharmacology, College of Osteopathic Medicine, University of New England, Biddleford, ME, 04005, USA

    Edward J. Bilsky

  3. Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, 23298, USA

    S. Stevens Negus

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Paudel, K.S. et al. (2009). Development of Opioid Transdermal Delivery Systems. In: Dean, R.L., Bilsky, E.J., Negus, S.S. (eds) Opiate Receptors and Antagonists. Contemporary Neuroscience. Humana Press. https://doi.org/10.1007/978-1-59745-197-0_38

Download citation

Publish with us

Policies and ethics

Search

Navigation